Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial
FRANKFURT (Reuters) - Merck KGaA and Pfizer's cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Immunotherapy | Lung Cancer | Merck | Pfizer